NasdaqGS - Nasdaq Real Time Price USD

Repligen Corporation (RGEN)

Compare
150.93 +0.18 (+0.12%)
At close: August 30 at 4:00 PM EDT
150.93 0.00 (0.00%)
After hours: August 30 at 4:21 PM EDT
Loading Chart for RGEN
DELL
  • Previous Close 150.75
  • Open 151.12
  • Bid 150.56 x 200
  • Ask 151.12 x 200
  • Day's Range 148.85 - 152.33
  • 52 Week Range 110.45 - 211.13
  • Volume 3,728,546
  • Avg. Volume 898,477
  • Market Cap (intraday) 8.453B
  • Beta (5Y Monthly) 0.95
  • PE Ratio (TTM) --
  • EPS (TTM) -0.03
  • Earnings Date Oct 29, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 192.07

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

www.repligen.com

1,783

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RGEN

View More

Performance Overview: RGEN

Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RGEN
16.06%
S&P 500
18.42%

1-Year Return

RGEN
12.30%
S&P 500
25.59%

3-Year Return

RGEN
45.28%
S&P 500
25.26%

5-Year Return

RGEN
62.27%
S&P 500
93.14%

Compare To: RGEN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RGEN

View More

Valuation Measures

Annual
As of 8/30/2024
  • Market Cap

    8.45B

  • Enterprise Value

    8.38B

  • Trailing P/E

    466.37

  • Forward P/E

    105.26

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.06

  • Price/Book (mrq)

    4.25

  • Enterprise Value/Revenue

    13.91

  • Enterprise Value/EBITDA

    91.14

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.32%

  • Return on Assets (ttm)

    0.19%

  • Return on Equity (ttm)

    -0.10%

  • Revenue (ttm)

    602.35M

  • Net Income Avi to Common (ttm)

    -1.9M

  • Diluted EPS (ttm)

    -0.03

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    809.15M

  • Total Debt/Equity (mrq)

    37.40%

  • Levered Free Cash Flow (ttm)

    120.45M

Research Analysis: RGEN

View More

Company Insights: RGEN

Research Reports: RGEN

View More

People Also Watch